Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 331,772 shares of the company’s stock after selling 1,967 shares during the quarter. Principal Financial Group Inc.’s holdings in Neurocrine Biosciences were worth $31,821,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the stock. First Horizon Advisors Inc. lifted its holdings in Neurocrine Biosciences by 61.7% in the third quarter. First Horizon Advisors Inc. now owns 1,177 shares of the company’s stock worth $119,000 after purchasing an additional 449 shares during the period. Mackenzie Financial Corp lifted its holdings in Neurocrine Biosciences by 51.7% in the third quarter. Mackenzie Financial Corp now owns 14,726 shares of the company’s stock worth $1,412,000 after purchasing an additional 5,017 shares during the period. Congress Asset Management Co. MA lifted its holdings in Neurocrine Biosciences by 6.7% in the third quarter. Congress Asset Management Co. MA now owns 1,011,772 shares of the company’s stock worth $97,039,000 after purchasing an additional 63,207 shares during the period. Meeder Asset Management Inc. lifted its holdings in Neurocrine Biosciences by 460.0% in the third quarter. Meeder Asset Management Inc. now owns 504 shares of the company’s stock worth $48,000 after purchasing an additional 414 shares during the period. Finally, Keybank National Association OH lifted its holdings in Neurocrine Biosciences by 14.1% in the third quarter. Keybank National Association OH now owns 9,267 shares of the company’s stock worth $889,000 after purchasing an additional 1,143 shares during the period. 94.20% of the stock is owned by institutional investors and hedge funds.

In other Neurocrine Biosciences news, insider Eiry Roberts sold 2,632 shares of the company’s stock in a transaction that occurred on Monday, January 10th. The stock was sold at an average price of $74.50, for a total transaction of $196,084.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matt Abernethy sold 1,645 shares of the company’s stock in a transaction that occurred on Wednesday, December 1st. The stock was sold at an average price of $82.59, for a total value of $135,860.55. The disclosure for this sale can be found here. In the last three months, insiders sold 32,543 shares of company stock valued at $2,748,688. 4.30% of the stock is currently owned by company insiders.

Shares of NBIX opened at $78.36 on Friday. The company has a market capitalization of $7.43 billion, a price-to-earnings ratio of 17.15 and a beta of 0.74. The business’s 50-day moving average is $84.37 and its 200-day moving average is $92.34. Neurocrine Biosciences, Inc. has a fifty-two week low of $71.88 and a fifty-two week high of $120.27. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.45 and a quick ratio of 4.34.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, November 1st. The company reported $0.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.51 by ($0.28). The firm had revenue of $296.00 million during the quarter, compared to the consensus estimate of $297.02 million. Neurocrine Biosciences had a net margin of 41.59% and a return on equity of 35.89%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.62) EPS. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 1.63 earnings per share for the current fiscal year.

Several research firms recently weighed in on NBIX. JPMorgan Chase & Co. raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and set a $124.00 price objective for the company in a report on Wednesday, November 17th. Oppenheimer upped their price target on shares of Neurocrine Biosciences from $140.00 to $154.00 and gave the company an “outperform” rating in a report on Wednesday, December 8th. SVB Leerink reissued a “market perform” rating on shares of Neurocrine Biosciences in a report on Monday, October 18th. Zacks Investment Research raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, December 8th. Finally, Mizuho upped their price target on shares of Neurocrine Biosciences from $99.00 to $103.00 and gave the company a “neutral” rating in a report on Tuesday, November 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $116.81.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.

Featured Story: Backdoor Roth IRA Conversion and Strategy

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.